Eisai, TorreyPines to Collaborate in Alzheimer's Drug Development

Eisai announced on March 18 that the company has concluded an agreement with TorreyPines Therapeutics to collaborate in new drug development. Under the terms of the agreement, the two companies aim to develop a disease modifying agent for patients with Alzheimer's disease. Eisai will receive rights of first negotiation and refusal for new compounds identified by TorreyPines Therapeutics. If a promising compound is discovered, the two companies plan to conclude a commercialization agreement.
Japan Corporate News Network